Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes;Seguridad de los nuevos anticoagulantes orales con terapia dual anti-plaquetas en pacientes con síndrome coronario agudo

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages 573-577

  Tsu, Laura V ^a   Dager, William E ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL PRACTICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG SAFETY; EARLY TERMINATION OF CLINICAL TRIAL; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 84876278760     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R576     Document Type: Article

References (21)

1. Levine GN, Bates ER, Blankenship JC, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58: e44-122. doi: 10.1016/j.jacc.2011.08.007
2. You JJ, Singer DE, Howard PA, et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S. doi: 10.1378/chest.11-2304
3. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619. doi: 10.1093/eurheartj/ehs215.
4. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425. doi: 10.1161/CIR.0b013e3182742cf6
5. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-41.
6. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185-93. doi: 10.1161/CIRCULATIONAHA.112.114967
7. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374: 1967-74. doi: 10.1016/S0140-6736(09)61751-7
8. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 2010;121:2067-70. doi: 10.1161/CIRCULATIONAHA.109.924944
9. Valgimigli M, Campo G, Monti M, et al.; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589
10. Dewilde W, Oirbans T, Verheugt F, et al. WOEST (What is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting). NLM identifier: NCT00769938. http://clinicaltrials.gov/show/NCT00769938 (accessed 2012 Nov 28).
11. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. doi: 10.1056/NEJMoa1107039
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1140-51. doi:10.1056/NEJMoa0905561
13. Patel MR, Mahaffey KW, Jyotsna G, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. doi: 10.1056/NEJMoa1009638
14. Oldgren J, Budaj A, Granger CB, et al.; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9. doi: 10.1093/eurheartj/ehr113
15. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndromes: a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38. doi: 10.1016/S0140-6736(09)60738-8
16. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19. doi: 10.1056/NEJMoa1112277
17. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139
18. Alexander JH, Lopes RD, James S, et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708. doi: 10.1056/NEJMoa1105819
19. FDA briefing information. Dabigatran etexilate mesylate capsules, September 20, 2010, meeting of the Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenal-DrugsAdvisoryCommittee/UCM247244.pdf (accessed 2012 Aug 29).
20. Patel MR, Mahaffey KW, Jyotsna G, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(suppl):883-91. doi: 10.1056/NEJMoa1009638
21. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(suppl): 981-92. doi: 10.1056/NEJMoa1107039